Compare $GRI vs $LIMN | Chartloom

Compare

$GRI vs $LIMN

GRI Bio Inc · Liminatus Pharma Inc

GRI

GRI Bio Inc

LIMN

Liminatus Pharma Inc

Compare $GRI vs $LIMN

Comparing GRI Bio Inc and Liminatus Pharma Inc

GRIGRI Bio Inc

LIMNLiminatus Pharma Inc

GRIGRI Bio Inc

Market cap

$3M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-77.8%

52W performance

-96.7%

FCF yield

-338.3%

LIMNLiminatus Pharma Inc

Market cap

$253M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-88.3%

52W performance

-95.3%

FCF yield

-1.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

GRI

LIMN

Detailed metrics comparison

GRI

GRI Bio Inc

LIMN

Liminatus Pharma Inc

Market Cap

GRI$3M

LIMN$253M

Enterprise Value

GRI$-8M

LIMN$251M

Price

GRI$1.74

LIMN$3.76

P/E Ratio

GRIN/A

LIMNN/A

P/S Ratio

GRI0.00x

LIMN0.00x

EV/Sales

GRI0.00x

LIMN0.00x

EV/EBITDA

GRI0.00x

LIMN0.00x

P/B Ratio

GRI0.42x

LIMN17.43x

P/FCF Ratio

GRIN/A

LIMNN/A

EV/FCF

GRI0.76x

LIMN-62.96x

PEG Ratio

GRIN/A

LIMNN/A

Forward P/E (NTM)

GRIN/A

LIMNN/A

Forward P/S (NTM)

GRIN/A

LIMNN/A

Revenue (TTM)

GRI$0

LIMN$0

Revenue Growth (YoY)

GRIN/A

LIMNN/A

Forward Rev Growth

GRI0.0%

LIMN0.0%

Gross Margin (TTM)

GRI0.0%

LIMN0.0%

Operating Margin (TTM)

GRI0.0%

LIMN0.0%

EBITDA Margin (TTM)

GRI0.0%

LIMN0.0%

Net Margin (TTM)

GRI0.0%

LIMN0.0%

FCF Margin (TTM)

GRIN/A

LIMNN/A

Net Income (TTM)

GRI$-10M

LIMN$-13M

FCF (TTM)

GRI$-10M

LIMN$-4M

EPS (TTM)

GRI-$5.35

LIMN-$12.94

ROE (TTM)

GRI-13403.0%

LIMN0.0%

ROA (TTM)

GRI-10683.0%

LIMN-62234.0%

ROIC (TTM)

GRI-13403.0%

LIMN0.0%

Cash

GRI$11M

LIMN$3M

Debt

GRI$0

LIMN$1M

Net Cash/Debt

GRI$11M

LIMN$2M

Current Ratio (TTM)

GRI10.30x

LIMN1.12x

Quick Ratio (TTM)

GRI9.95x

LIMN0.99x

Debt/Equity (TTM)

GRI0.00x

LIMN4.80x

Debt/Assets (TTM)

GRI0.0%

LIMN0.0%

Interest Coverage (TTM)

GRIN/A

LIMNN/A

Net Debt/EBITDA (TTM)

GRI0.00x

LIMN0.00x

Beta

GRI-1.09

LIMN0.75

52W Performance

GRI-96.7%

LIMN-95.3%

YTD Performance

GRI-77.8%

LIMN-88.3%

% from 52W High

GRI-97.3%

LIMN-97.3%

% from 52W Low

GRI27.9%

LIMN14.3%

Asset Turnover (TTM)

GRI0.00x

LIMN0.00x

FCF Yield (TTM)

GRI-338.3%

LIMN-1.6%

Earnings Yield (TTM)

GRI-313.6%

LIMN-5.0%

Dividend Yield (TTM)

GRIN/A

LIMNN/A

Rule of 40

GRI0.0

LIMN0.0

EV/GP/RG

GRIN/A

LIMNN/A

Ticker research

View GRI research View LIMN research

Metric	GRI GRI Bio Inc	LIMN Liminatus Pharma Inc
Market & Valuation
Market Cap	$3M	$253M
Enterprise Value	$-8M	$251M
Price	$1.74	$3.76
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.42x	17.43x
P/FCF Ratio	N/A	N/A
EV/FCF	0.76x	-62.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-10M	$-13M
FCF (TTM)	$-10M	$-4M
EPS (TTM)	-$5.35	-$12.94
ROE (TTM)	-13403.0%	0.0%
ROA (TTM)	-10683.0%	-62234.0%
ROIC (TTM)	-13403.0%	0.0%
Financial Health
Cash	$11M	$3M
Debt	$0	$1M
Net Cash/Debt	$11M	$2M
Current Ratio (TTM)	10.30x	1.12x
Quick Ratio (TTM)	9.95x	0.99x
Debt/Equity (TTM)	0.00x	4.80x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-1.09	0.75
52W Performance	-96.7%	-95.3%
YTD Performance	-77.8%	-88.3%
% from 52W High	-97.3%	-97.3%
% from 52W Low	27.9%	14.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-338.3%	-1.6%
Earnings Yield (TTM)	-313.6%	-5.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View GRI research	View LIMN research

Valuation

P/S Ratio

GRI

0.00x

LIMN

0.00x

EV/FCF

LIMN

-62.96x

GRI

0.76x

Growth & revenue

Forward Revenue Growth

GRI

0.0%

LIMN

0.0%

Profitability & performance

Gross Margin

GRI

0.0%

LIMN

0.0%

ROE

LIMN

0.0%

GRI

-13403.0%

FCF Yield %

LIMN

-1.6%

GRI

-338.3%

52-Week Performance

LIMN

-95.3%

GRI

-96.7%

Detailed metrics comparison

GRI

GRI Bio Inc

LIMN

Liminatus Pharma Inc

Market Cap

GRI$3M

LIMN$253M

Enterprise Value

GRI$-8M

LIMN$251M

Price

GRI$1.74

LIMN$3.76

P/E Ratio

GRIN/A

LIMNN/A

P/S Ratio

GRI0.00x

LIMN0.00x

EV/Sales

GRI0.00x

LIMN0.00x

EV/EBITDA

GRI0.00x

LIMN0.00x

P/B Ratio

GRI0.42x

LIMN17.43x

P/FCF Ratio

GRIN/A

LIMNN/A

EV/FCF

GRI0.76x

LIMN-62.96x

PEG Ratio

GRIN/A

LIMNN/A

Forward P/E (NTM)

GRIN/A

LIMNN/A

Forward P/S (NTM)

GRIN/A

LIMNN/A

Revenue (TTM)

GRI$0

LIMN$0

Revenue Growth (YoY)

GRIN/A

LIMNN/A

Forward Rev Growth

GRI0.0%

LIMN0.0%

Gross Margin (TTM)

GRI0.0%

LIMN0.0%

Operating Margin (TTM)

GRI0.0%

LIMN0.0%

EBITDA Margin (TTM)

GRI0.0%

LIMN0.0%

Net Margin (TTM)

GRI0.0%

LIMN0.0%

FCF Margin (TTM)

GRIN/A

LIMNN/A

Net Income (TTM)

GRI$-10M

LIMN$-13M

FCF (TTM)

GRI$-10M

LIMN$-4M

EPS (TTM)

GRI-$5.35

LIMN-$12.94

ROE (TTM)

GRI-13403.0%

LIMN0.0%

ROA (TTM)

GRI-10683.0%

LIMN-62234.0%

ROIC (TTM)

GRI-13403.0%

LIMN0.0%

Cash

GRI$11M

LIMN$3M

Debt

GRI$0

LIMN$1M

Net Cash/Debt

GRI$11M

LIMN$2M

Current Ratio (TTM)

GRI10.30x

LIMN1.12x

Quick Ratio (TTM)

GRI9.95x

LIMN0.99x

Debt/Equity (TTM)

GRI0.00x

LIMN4.80x

Debt/Assets (TTM)

GRI0.0%

LIMN0.0%

Interest Coverage (TTM)

GRIN/A

LIMNN/A

Net Debt/EBITDA (TTM)

GRI0.00x

LIMN0.00x

Beta

GRI-1.09

LIMN0.75

52W Performance

GRI-96.7%

LIMN-95.3%

YTD Performance

GRI-77.8%

LIMN-88.3%

% from 52W High

GRI-97.3%

LIMN-97.3%

% from 52W Low

GRI27.9%

LIMN14.3%

Asset Turnover (TTM)

GRI0.00x

LIMN0.00x

FCF Yield (TTM)

GRI-338.3%

LIMN-1.6%

Earnings Yield (TTM)

GRI-313.6%

LIMN-5.0%

Dividend Yield (TTM)

GRIN/A

LIMNN/A

Rule of 40

GRI0.0

LIMN0.0

EV/GP/RG

GRIN/A

LIMNN/A

Ticker research

View GRI research View LIMN research

Metric	GRI GRI Bio Inc	LIMN Liminatus Pharma Inc
Market & Valuation
Market Cap	$3M	$253M
Enterprise Value	$-8M	$251M
Price	$1.74	$3.76
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.42x	17.43x
P/FCF Ratio	N/A	N/A
EV/FCF	0.76x	-62.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-10M	$-13M
FCF (TTM)	$-10M	$-4M
EPS (TTM)	-$5.35	-$12.94
ROE (TTM)	-13403.0%	0.0%
ROA (TTM)	-10683.0%	-62234.0%
ROIC (TTM)	-13403.0%	0.0%
Financial Health
Cash	$11M	$3M
Debt	$0	$1M
Net Cash/Debt	$11M	$2M
Current Ratio (TTM)	10.30x	1.12x
Quick Ratio (TTM)	9.95x	0.99x
Debt/Equity (TTM)	0.00x	4.80x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-1.09	0.75
52W Performance	-96.7%	-95.3%
YTD Performance	-77.8%	-88.3%
% from 52W High	-97.3%	-97.3%
% from 52W Low	27.9%	14.3%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-338.3%	-1.6%
Earnings Yield (TTM)	-313.6%	-5.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View GRI research	View LIMN research